INS and coronary artery disorder: More specifically, Gonadotropin-releasing hormone (GnRH) agonists increase LDL-cholesterol and triglyceride levels, visceral fat, and insulin resistance and decrease lean body mass and glucose tolerance, leading to accelerated atherosclerosis and coronary artery disease (CAD) events, HF, and arrhythmias [144,145].